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Highlights 
 Horses with pre-clinical pituitary pars intermedia dysfunction (PPID) did not have higher 
fecal egg counts (EPG) than healthy controls. 
 In horses with pre-clinical PPID that received treatment with pergolide, EPG decreased 
over time compared to baseline EPG. 
 There was no significant difference in EPG between pergolide and placebo treated animals. 
 
Abstract  
Pituitary pars intermedia dysfunction (PPID) has been associated with diminished 
immune response in aged horses. This prospective study hypothesised that this may result in 
increased strongyle egg shedding in affected animals and that horses treated with pergolide 
would have reduced fecal egg counts (eggs per gram, EPG) compared to placebo-treated 
animals. Adrenocorticotropic hormone (ACTH) concentrations and EPG were tested in 48 
horses. There were no significant differences in baseline EPG between horses with pre-clinical 
PPID and healthy controls.  There was no significant difference in EPG between horses with 
PPID after treatment with pergolide and placebo-treated animals. Using EPG as a marker of 
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immune function, these results did not support a proposed decrease in immune function in 
horses with pre-clinical PPID.  
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Pituitary pars intermedia dysfunction (PPID) is a common disorder affecting about 20% 
of aged horses (McGowan et al., 2013b). It has been suggested that changes in circulating 
pituitary pars intermedia peptides are responsible for increased susceptibility to infection due 
to their role in immune function (McFarlane, 2014). These chronic effects on immune function 
could diminish defenses against intestinal parasites. We therefore hypothesized that horses with 
PPID would have higher fecal egg counts (eggs per gram, EPG) compared to healthy controls. 
Furthermore, we expected lower EPG in horses with pre-clinical PPID after 3 months of 
treatment with pergolide compared to placebo-treated animals. 
 
In this prospective study, horses and ponies owned by a foundation for retired equids 
were examined clinically, and plasma ACTH and EPG were assessed. The study aimed to 
screen a population of aged horses for early onset of disease. None of the animals showed 
obvious clinical signs of PPID. The study was approved by the Animal Experimentation 
Committee of the Cantons of Jura and Berne, Switzerland (authorization number JU EXPE01; 
approval date 3 June 2014). The last anthelmintic treatment was administered at least 4 months 
prior to study commencement. The study period ranged from 1 July 2014 to 31 January 2015. 
Blood was sampled on two occasions: (1) all horses in July (ACTH1); and (2) in horses with 
pre-clinical PPID again in January (ACTH2). ACTH analysis was performed using a 
chemoluminescence immunoassay (Perkins et al., 2002). To exclude horses with equine 
metabolic syndrome, an oral sugar test was performed in July according to the protocol 
described by Schuver et al. (2014). For the purposes of the study, the PPID group included 
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horses with ACTH concentrations >35 pg/mL in July1. The control group (CON) consisted of 
healthy horses with ACTH concentrations below the upper limit of the reference range. Horses 
in the PPID group were treated with 0.002 mg/kg BW pergolide (Prascend, Boehringer 
Ingelheim; PER) or placebo (PLA) orally for 3 months (1 October 2014 to 31 January 2015). 
Allocation to study group PER or PLA was determined by simple randomization using 
dedicated software 2. Placebo treatment consisted of the same tablet as pergolide (Prascend, 
Boehringer Ingelheim) without the active ingredient.  
 
Fecal samples were collected once daily during a 5-day period from freshly voided 
feces. A combined sedimentation-flotation method was performed using a previously published 
method (Boch and Bauer, 2006). Fecal egg counts were performed using the McMaster method 
(Kaufmann, 2013) on three occasions: (1) EPG-1 baseline: August; all horses; (2) EPG-2 
baseline: September; all horses; and (3) EPG after treatment: January, PPID group treated with 
pergolide (PER) or placebo (PLA). For a hypothesised increase in EPG of approximately 100% 
in horses with PPID compared to healthy controls (McFarlane et al., 2010), a required sample 
size of 50 horses (25 horses with PPID and 25 control horses) was calculated 3. Data was 
analysed using NCSS8 statistical software. P-values < 0.05 were considered statistically 
significant. Comparisons of age distribution and EPG between groups (PPID vs. CON and PER 
vs. PLA) were performed using Kruskal-Wallis one-way ANOVA on ranks for non-parametric 
values. Correlations between ACTH1, EPG-1 and EPG-2 and between ACTH2 and EPG-3 were 
calculated using linear regression. Baseline fecal egg counts (EPG-1 and EPG-2) were 
                                                          
1 See: Durham, A.E., 2016. Seasonal Changes in ACTH Secretion. 
http://liphookequinehospital.co.uk/wp-content/uploads/Seasonal-Changes-in-ACTH-
Secretion2.pdf (accessed 25 March 2018) 
2 See: Research Randomizer. www.randomizer.org (accessed 25 March 2018). 
3 See: Sample Size Calculator. http://clincalc.com/stats/samplesize.aspx (accessed 25 March 
2018). 
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compared to EPG after treatment (EPG-3) in the PER and PLA groups using repeated measures 
analysis of variance. 
 
Forty-eight horses with a mean ± standard deviation (SD) age of 24.8 ± 3.6 years (range, 
14 to 32 years) were included in the study. Twenty-two were geldings and 26 were mares. 
ACTH1 values ranged from 10.6 to 235 pg/mL (median 37.3 pg/mL; standard error [SE] 6.9). 
Twenty-four horses (50%) were diagnosed with PPID and 24 healthy horses (50%) were 
assigned to the CON group. Horses in the PPID group were significantly older than horses in 
the CON group (P<0.01; Table 1). Reported results for EPG included only strongyle eggs and 
are displayed in Table 1. In both groups, there was no significant difference between baseline 
EPG-1 (P=0.66) and baseline EPG-2 (P=0.71; Table 1). Plotting ACTH1 concentrations against 
baseline EPG-1 and EPG-2 did not reveal statistically significant correlations (P=0.26 and 
P=0.15, respectively; Figs. 1a, b). Of the 24 horses with pre-clinical PPID, five died of unrelated 
causes during the treatment period and were therefore excluded from the analysis for ACTH2 
and EPG-3. Ten horses in the PPID group were treated with pergolide and nine horses with 
placebo. ACTH2 concentrations ranged between 7.4 and 479 pg/mL (median 45.4 pg/mL; SE 
24.5). There was no significant difference in age (P=0.05) or ACTH1 values (P=0.7) between 
the PER and PLA groups, but ACTH2 values were significantly lower in the PER group 
(P<0.01; Table 1). There was no significant difference in EPG after treatment between the PER 
and PLA groups (P=0.05; Table 1). EPG-3 was significantly lower in the PER groups compared 
to baseline values (P=0.03), but not in the PLA groups (P=0.88). ACTH2 concentrations were 
not significantly correlated with EPG-3 after treatment (Fig. 2).  
 
Contrary to our hypothesis, horses with pre-clinical PPID did not have higher EPG than 
healthy control horses. In the PPID group, the difference in EPG after treatment in horses 
treated with pergolide compared with placebo-treated animals did not reach statistical 
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significance. There was a statistically significant difference between baseline EPG and EPG 
after treatment in horses treated with pergolide compared to placebo-treated animals. Whether 
this was due to the suspected influence of pergolide on the immune system, the gastrointestinal 
system of the horse, or direct dopaminergic effects on the parasite remains unclear. Direct 
effects on parasite burden would explain why differences did not seem to be associated with 
host disease status, but were associated with pergolide treatment, although this conclusion 
remains speculative at this stage. This part of the study was statistically underpowered and the 
results need to be confirmed with larger experimental groups, as well as ACTH and fecal testing 
at the same time of the year.  
 
We defined the PPID group on the basis of ACTH concentrations rather than clinical 
signs, as none of the horses showed marked signs of advanced clinical disease. However, a 
reference standard method to diagnose PPID in cases with only subtle clinical signs and mildly 
elevated ACTH values remains unavailable. In future studies, additional ACTH measurements 
could be performed in autumn to increase the chances of correctly identifying affected animals 
(McGowan et al., 2013a). Our results differ from those of an earlier study where horses with 
PPID had higher EPG counts before and after anthelmintic treatment compared to healthy 
controls (McFarlane et al., 2010).  The previous study included horses with more advanced 
disease, while our study investigated aged horses without obvious signs of PPID. Therefore, 
the discrepancy in study results might be based on the difference in the inclusion criteria.  
 
Limitations of the present study include several important factors affecting parasite 
infection levels and thus EPG. Some of these factors may have been attenuated by standardised 
management protocols, while other factors, such as the immune status of the animal could not 
be addressed.  
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In our study, a proposed reduction in immune function in horses with pre-clinical PPID 
was not supported by increased fecal egg shedding by intestinal strongyles. Differences in EPG 
in horses with pre-clinical PPID after treatment with pergolide compared with placebo have not 
previously been reported. 
 
Conflict of interest statement 
None of the authors of this paper has a financial or personal relationship with other 
people or organizations that could inappropriately influence or bias the content of the paper. 
 
Acknowledgements 
The authors thank ‘Die Stiftung für das Pferd’ for access to the study population and 
good collaboration, Synlab for performing all blood analyses and Sylvie Froidevaux for help 
with the coprologic examinations. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
References 
Boch, J., Bauer, C., 2006. In: Veterinärmedizinische Parasitologie, sixth Edn. Paul Parey 
Verlag, Stuttgart, Germany, pp. 87-88. 
 
Kaufmann, J., 2013. In: Parasitic infections of domestic animals: A diagnostic manual, first 
Edn. Birkhäuser, Basel, Switzerland, pp. 7. 
 
McFarlane, D., 2014. Pathophysiology and clinical features of pituitary pars intermedia 
dysfunction. Equine Veterinary Education 26, 592-598. 
 
McFarlane, D., Hale, G.M., Johnson, E.M., Maxwell, L.K., 2010. Fecal egg counts after 
anthelmintic administration to aged horses and horses with pituitary pars intermedia 
dysfunction. Journal of the American Veterinary Medical Association 236, 330-334. 
 
McGowan, T.W., Pinchbeck, G.P., Mc Gowan, C.M., 2013a. Evaluation of basal plasma alpha-
melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for 
the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses. 
Equine Veterinary Journal 45, 66-73. 
 
McGowan, T.W., Pinchbeck, G.P., McGowan, C.M., 2013b. Prevalence, risk factors and 
clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses. 
Equine Veterinary Journal 45, 74-79. 
 
Perkins, G.A., Lamb, S., Erb, H.N., Schanbacher, B., Nydam, D.V., Divers, T.J., 2002. Plasma 
adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for 
equine Cushing's disease with cyproheptadine or pergolide. Equine Veterinary Journal 
34, 679-685. 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
Figure legends 
Fig. 1. Correlation of the concentration of adrenocorticotropic hormone (ACTH) in July 
(ACTH1, pg/mL) and baseline fecal egg counts (eggs per gram feces, EPG) of all horses in 
August (Baseline EPG 1; a) and in September (Baseline EPG 2; b).  
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Fig. 2. Correlation of the concentration of adrenocorticotropic hormone (ACTH) in January 
(ACTH2) and fecal egg counts (eggs per gram, EPG) after treatment (EPG 3 after treatment). 
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Table 1  
Mean ± standard deviation (SD) age, median (range) adrenocorticotropic hormone (ACTH) 
concentrations (pg/mL) and median (range) fecal egg counts (egg per gram faeces, EPG) in 
horses with pituitary pars intermedia dysfunction (PPID, n=24), control horses (CON, n=24) 
and horses with PPID treated with pergolide (PER, n=10) or with placebo (PLA, n=9). 
 PPID (n=24) CON (n=24) PER (n=10) PLA (n=9) 
     
Age (years) 26.7 ± 2.2 22.9 ± 3.7 27.4 ± 2.2 25.6 ± 1.8 
     
ACTH1 (pg/mL) 
a
 78.3 (39.1-235) 19.5 (10.6-35.5) 75.2 (39.1-195) 80.7 (39.3-127) 
ACTH2
 (pg/mL) b ‒ ‒ 25.9 (7.4-50.1) 73.2 (37.8-479) 
     
EPG-1 c 50 (0-400) 50 (0-550) ‒ ‒ 
EPG-2 d 100 (0-650) 100 (0-750) ‒ ‒ 
EPG-3 e ‒ ‒ 0 (0-100) 100 (0-650) 
a Baseline ACTH concentrations measured in July (all horses; n=48).  
b ACTH concentrations after 3 months of treatment with pergolide or placebo in January (horses 
in PER and PLA groups; n=19). The number of horses in this category is n=19 as five horses 
from group PPID died before blood samples for ACTH2 were collected 
c Baseline fecal egg counts in August.  
d Baseline fecal egg counts in September.  
e Fecal egg counts in January after 3 months of treatment with pergolide or placebo.  
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